Post-earnings recap
Reported
Wed, Feb 17, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss per share of $0.15, which was slightly better than expected. However, the lack of revenue data and no guidance led to a 2.36% decline in stock price. Investors may be cautious as they await more information on clinical trials and future data releases.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | +2.60% |
| Revenue | N/A | N/A | N/A |
Overall, management remains focused on advancing their pipeline. They emphasized the significance of future developments for the company.
Management expressed optimism about ongoing clinical trials.
They highlighted the importance of upcoming data releases in the near future.